Sandu Pharmaceuticals Limited (BOM:524703)
India · Delayed Price · Currency is INR 39.50
-0.70 (-1.74%)
At close: Dec 5, 2025
Sandu Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Operating Revenue | 667.62 | 671.92 | 672.81 | 653.49 | 655.01 | 587.55 | Upgrade |
| 667.62 | 671.92 | 672.81 | 653.49 | 655.01 | 587.55 | Upgrade | |
Revenue Growth (YoY) | -1.48% | -0.13% | 2.96% | -0.23% | 11.48% | 21.28% | Upgrade |
Cost of Revenue | 339.35 | 342.36 | 346.4 | 332.83 | 378.31 | 363.39 | Upgrade |
Gross Profit | 328.27 | 329.57 | 326.41 | 320.66 | 276.7 | 224.17 | Upgrade |
Selling, General & Admin | 185.12 | 181.46 | 177.89 | 169.74 | 138.63 | 118.44 | Upgrade |
Other Operating Expenses | 114.87 | 120.46 | 125.57 | 126.05 | 109.33 | 84.14 | Upgrade |
Operating Expenses | 306.83 | 308.62 | 309.29 | 300.97 | 253.26 | 208.15 | Upgrade |
Operating Income | 21.44 | 20.94 | 17.12 | 19.69 | 23.44 | 16.02 | Upgrade |
Interest Expense | -1 | -0.97 | -0.54 | -0.72 | -0.74 | -0.65 | Upgrade |
Interest & Investment Income | 1.68 | 1.68 | 4.21 | 3.27 | 0.83 | 1.94 | Upgrade |
Other Non Operating Income (Expenses) | -0.15 | -0.07 | -0.06 | -0.08 | -0.36 | -0.5 | Upgrade |
EBT Excluding Unusual Items | 21.97 | 21.59 | 20.73 | 22.17 | 23.17 | 16.81 | Upgrade |
Pretax Income | 21.97 | 21.59 | 20.73 | 22.17 | 23.17 | 16.81 | Upgrade |
Income Tax Expense | 5.65 | 6.07 | 6.12 | 6.96 | 7.27 | 5.88 | Upgrade |
Net Income | 16.32 | 15.52 | 14.61 | 15.21 | 15.89 | 10.93 | Upgrade |
Net Income to Common | 16.32 | 15.52 | 14.61 | 15.21 | 15.89 | 10.93 | Upgrade |
Net Income Growth | 11.74% | 6.19% | -3.90% | -4.33% | 45.47% | 51.67% | Upgrade |
Shares Outstanding (Basic) | 10 | 10 | 10 | 9 | 8 | 7 | Upgrade |
Shares Outstanding (Diluted) | 10 | 10 | 10 | 9 | 9 | 7 | Upgrade |
Shares Change (YoY) | 0.98% | - | 2.42% | 10.93% | 20.08% | - | Upgrade |
EPS (Basic) | 1.69 | 1.61 | 1.51 | 1.73 | 1.99 | 1.54 | Upgrade |
EPS (Diluted) | 1.68 | 1.60 | 1.51 | 1.61 | 1.87 | 1.54 | Upgrade |
EPS Growth | 10.43% | 5.96% | -6.21% | -13.90% | 21.43% | 51.39% | Upgrade |
Free Cash Flow | 2.44 | 0.1 | -6.65 | -8.48 | 1.08 | 74.63 | Upgrade |
Free Cash Flow Per Share | 0.25 | 0.01 | -0.69 | -0.90 | 0.13 | 10.54 | Upgrade |
Dividend Per Share | 0.800 | 0.800 | 0.800 | 0.750 | 0.750 | 0.500 | Upgrade |
Dividend Growth | - | - | 6.67% | - | 50.00% | - | Upgrade |
Gross Margin | 49.17% | 49.05% | 48.51% | 49.07% | 42.24% | 38.15% | Upgrade |
Operating Margin | 3.21% | 3.12% | 2.54% | 3.01% | 3.58% | 2.73% | Upgrade |
Profit Margin | 2.44% | 2.31% | 2.17% | 2.33% | 2.43% | 1.86% | Upgrade |
Free Cash Flow Margin | 0.36% | 0.01% | -0.99% | -1.30% | 0.16% | 12.70% | Upgrade |
EBITDA | 26.04 | 25.4 | 21.3 | 23.23 | 26.95 | 19.8 | Upgrade |
EBITDA Margin | 3.90% | 3.78% | 3.17% | 3.55% | 4.11% | 3.37% | Upgrade |
D&A For EBITDA | 4.59 | 4.46 | 4.18 | 3.54 | 3.51 | 3.77 | Upgrade |
EBIT | 21.44 | 20.94 | 17.12 | 19.69 | 23.44 | 16.02 | Upgrade |
EBIT Margin | 3.21% | 3.12% | 2.54% | 3.01% | 3.58% | 2.73% | Upgrade |
Effective Tax Rate | 25.70% | 28.11% | 29.51% | 31.41% | 31.39% | 35.00% | Upgrade |
Revenue as Reported | 669.22 | 673.6 | 677.04 | 656.76 | 655.83 | 589.49 | Upgrade |
Advertising Expenses | - | 69.92 | 74.72 | 56.56 | 47.39 | 35.6 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.